Planegg, Germany

Daniel Weinfurtner

This inventor holds 2 USPTO granted patents and 1 published patent application and 1 EPO patent. Top assignee: Morphosys Ag. Active years: 2022-2026.

USPTO Granted Patents = 2 

% Patents Active = 100.0

 

Average Co-Inventor Count = 5.0

ph-index = 1


Company Filing History:


Years Active: 2022-2026

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Daniel Weinfurtner: Innovator in Pharmaceutical Formulations

Introduction

Daniel Weinfurtner is a notable inventor based in Planegg, Germany. He has made significant contributions to the field of pharmaceuticals, particularly in the development of antibody formulations. His work is characterized by a focus on innovative solutions that address critical medical needs.

Latest Patents

Daniel Weinfurtner holds a patent for an anti-CD19 antibody formulation. This pharmaceutical formulation is designed to enhance the efficacy of treatments targeting CD19, a protein commonly associated with certain types of cancer. His patent represents a crucial advancement in the development of targeted therapies.

Career Highlights

Weinfurtner is associated with MorphoSys AG, a leading biotechnology company specializing in the development of innovative therapies for cancer and autoimmune diseases. His role at MorphoSys AG has allowed him to contribute to groundbreaking research and development efforts in the pharmaceutical industry.

Collaborations

Throughout his career, Daniel has collaborated with esteemed colleagues, including Martin Hessling and Bodo Brocks. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas.

Conclusion

Daniel Weinfurtner's contributions to pharmaceutical formulations, particularly in the area of anti-CD19 antibodies, highlight his role as a key innovator in the field. His work continues to influence the development of targeted therapies that can improve patient outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…